Efficacy and safety profile of anifrolumab in skin lesions of systemic lupus erythematosus
- PMID: 40052237
- DOI: 10.1111/jdv.20616
Efficacy and safety profile of anifrolumab in skin lesions of systemic lupus erythematosus
References
REFERENCES
-
- Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211–221.
-
- Amoura Z, Bader‐Meunier B, Antignac M, Bardin N, Belizna C, Belot A, et al. French protocol for the diagnosis and management of systemic lupus erythematosus. Rev Med Interne. 2024;45(9):559–599.
-
- The CLASI (cutaneous LE disease area and severity index): an outcome instrument for cutaneous lupus erythematosus. J Am Acad Dermatol. 2005;52(3):AB6.
-
- Niebel D, De Vos L, Fetter T, Brägelmann C, Wenzel J. Cutaneous lupus erythematosus: an update on pathogenesis and future therapeutic directions. Am J Clin Dermatol. 2023;24(4):521–540.
-
- Grolleau C, Poisot T, Hadjadj J, Jachiet M, Mahevas T, Le Buanec H, et al. Transcriptomic analysis of one patient with lupus skin lesions treated with anifrolumab. J Eur Acad Dermatol Venereol. 2025;39:e306–e309. https://doi.org/10.1111/jdv.20283
Publication types
LinkOut - more resources
Full Text Sources